The study found that curcumin is able to induce apoptosis (normal programmed cell death) in the most resistant breast cancer cells that
lack estrogen receptors.
But recent work shows that while these cancers
lack estrogen receptors, progesterone receptors, and aren't driven by the gene HER2, up to a third of these tumors express the androgen receptor — clinical trials are underway to inhibit the androgen receptor in these tumors in much the same way that the drug Tamoxifen inhibits estrogen receptor in estrogen - receptor - positive breast cancers.
Triple - negative breast cancers are those whose cells
lack estrogen receptors and progesterone receptors, and do not have an excess of the HER2 protein on their surfaces.
Not exact matches
The draft
lacks a clear description of the criteria for eliminating an increasing number of non-GLP studies that indicate the possibility of toxic effects that are not mediated by interaction of BPA with the
estrogen receptor, and the Subcommittee does not agree with the exclusion of the non-GLP studies in the safety assessment.
Triple negative breast cancer is especially hard to treat because it
lacks the
receptors, such as the
estrogen receptor, targeted with other cancer drugs.
It is called triple negative because it
lacks receptors for the hormones
estrogen and progesterone and makes little of a protein called HER2.
It derives its name from the
lack of
receptors for
estrogen, progesterone and Her2.
They massively overexpress the
estrogen receptor to compensate for a
lack of
estrogen.
Ince and his team found that although TNBC
lacks the three
receptors that fuel most breast cancers —
estrogen receptors, progesterone
receptors, and human epidermal growth factor
receptor 2 — it does express androgen
receptors (AR) and vitamin D
receptors (VDR).
Triple - negative breast cancer (TNBC), a tumor type defined by its
lack of
estrogen receptor, progesterone
receptor, and Her2 (ERBB2) amplification, accounts for 16 % of breast cancers.
Chemotherapy is a key part of the standard treatment regimen for triple - negative breast cancer patients whose cancer
lacks expression of
estrogen and progesterone
receptors and the human epidermal growth factor
receptor 2...
Despite marked advances in breast cancer therapy, basal - like breast cancer (BBC), an aggressive subtype of breast cancer usually
lacking estrogen and progesterone
receptors, remains difficult to treat.
Triple - negative tumors are in the 4th category, and are
lacking receptors for
estrogen, progesterone, and a protein known as HER2 / neu.